MedTrace Logo

Biomarkers of Immune-Related Toxicity

NCT03409016 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2025-09-05

No results posted yet for this study

Summary

This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.

Conditions

Interventions

OTHER

Blood Testing

Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.

Sponsors & Collaborators

  • Cancer League of Colorado

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Sarah L Davis, MD · University of Colorado, Denver

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2025-05-28
Completion
2026-05-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03409016 on ClinicalTrials.gov